Cell-Based Therapies and Bembaneprocel

At the 2024 American Academy of Neurology Annual Meeting, NeurologyLive^® sat down with Parkinson disease (PD) expert Daniel Kremens, MD, JD, to discuss some of the top data being presented at the meeting on novel approaches in development for the treatment of the movement disorder. Kremens discussed these various presentations, offering his perspective on the clinical landscape.

In this segment, Kremens discussed new data from an early-stage trial assessing bemdaneprocel, a stem cell therapy, in patients with PD. He gave his reaction to the findings presented at AAN and how they will impact clinical care going forward.

00:00 – 18-month data on bemdaneprocel for Parkinson disease

Transcript below edited for clarity.

Daniel Kremens, MD, JD: Bemdaneprocel is a pluripotent stem cell therapy that's under investigational use for Parkinson disease. There was data presented earlier that looked through the first year, and that suggested that again, the drug was well tolerated in the 12 participants who received it, with signals and improvement in UPDRS (Unified Parkinson's Disease Rating Scale) motor scores. And what we're going to learn at this year's conference is looking at how these patients have continued through month 18. I think this is really exciting time in Parkinson disease, where we're looking at these truly not just symptomatic therapies, but disease-modifying therapies by introducing these pluripotent stem cells that are dopaminergic precursors to see whether we could really impact the actual disease state long term.